Black Women in Atlanta Need More PrEP Access. Researchers and Advocates Are Working to Make This a Reality.
While most pre-exposure prophylaxis (PrEP) campaigns focus on gay and bisexual men, Fulton County Board of Health officials and advocates look for solutions to get PrEP to black women.
This population is under-represented in HIV data, and few prevention or treatment interventions exist to support them. A new meta-analysis hopes to paint a picture of what's needed.
Oct. 10, 2019: Long-term viral suppression = zero genital tract shedding among women; HIV treatment initiation and sexual risk among MSM; PrEP interest vs. uptake among trans women of color; polypharmacy among people living with HIV.
The FDA approved the fixed-dose combination of emtricitabine and tenofovir alafenamide for PrEP, but advocates hope to see more research on the HIV prevention drug's efficacy for receptive vaginal sex for cisgender women and transgender men.
Asa Radix, M.D., M.P.H., discusses providing quality care to transgender people. It can be done.
Will potential study participants choose a vaccine trial over getting access to PrEP?
The US Preventive Services Task Force released its final ruling in JAMA.
Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.
"For us who focus on HIV prevention research, it is paramount that we go where the epidemic is in this country," said Michele Andrasik, Ph.D.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.